. 2024 May 21;35(7):980–983. doi: 10.1681/ASN.0000000000000381

Table 2.

Odds ratios for accelerated measured GFR and eGFR decline per doubling or SD increase in baseline protein concentration

Protein	Unadjusted		P Value for Difference	Model 1		P Value for Difference	Model 2		P Value for Difference
Protein	OR	95% CI	P Value for Difference	OR	95% CI	P Value for Difference	OR	95% CI	P Value for Difference
MCP-1^a
mGFR	1.27	0.90 to 1.79		1.21	0.81 to 1.80		1.24	0.82 to 1.87
eGFRcre	1.11	0.80 to 1.55	0.59	1.11	0.79 to 1.57	0.75	1.10	0.78 to 1.56	0.67
eGFRcys	1.31	0.98 to 1.75	0.88	1.28	0.91 to 1.79	0.84	1.00	0.62 to 1.63	0.51
eGFRcyscre	1.13	0.82 to 1.55	0.62	1.08	0.76 to 1.53	0.67	1.01	0.70 to 1.46	0.48
TRAIL-R2^a
mGFR	1.32^b	1.02 to 1.70^b		0.97	0.68 to 1.40		1.06	0.73 to 1.54
eGFRcre	1.53^b	1.18 to 1.97^b	0.43	1.41^b	1.07 to 1.86^b	0.10	1.27	0.94 to 1.71	0.47
eGFRcys	2.27^b	1.50 to 3.44^b	0.03^b	2.18^b	1.49 to 3.18^b	0.002^b	1.33	0.78 to 2.29	0.50
eGFRcyscre	1.52^b	1.17 to 1.97^b	0.44	1.34	0.99 to 1.83	0.17	1.01	0.63 to 1.63	0.88
FABP4^a
mGFR	0.90	0.76 to 1.06		0.88	0.71 to 1.09		1.01	0.79 to 1.28
eGFRcre	1.18	0.94 to 1.48	0.06	1.17	0.86 to 1.60	0.13	1.02	0.76 to 1.35	0.95
eGFRcys	1.34^b	1.08 to 1.66^b	0.004^b	1.74^b	1.25 to 2.44^b	0.001^b	1.01	0.68 to 1.48	1.00
eGFRcyscre	1.32^b	1.04 to 1.68^b	0.01^b	1.44^b	1.00 to 2.06^b	0.02^b	1.11	0.79 to 1.55	0.64
TNFR-2
mGFR	1.31^b	1.13 to 1.53^b		1.09	0.91 to 1.32		1.25^b	1.03 to 1.51^b
eGFRcre	1.24^b	1.07 to 1.44^b	0.62^c	1.19^b	1.02 to 1.39^b	0.50^d	1.07	0.91 to 1.26	0.23
eGFRcys	2.57^b	2.07 to 3.18^b	<0.001^b	2.45^b	1.93 to 3.12^b	<0.001^b	1.10	0.82 to 1.47	0.47
eGFRcyscre	1.44^b	1.22 to 1.70^b	0.43	1.31^b	1.10 to 1.55^b	0.17	0.95	0.77 to 1.17	0.06
CD40Lig
mGFR	1.03	0.88 to 1.19		1.01	0.85 to 1.20		0.98	0.82 to 1.18
eGFRcre	1.10	0.96 to 1.26	0.48	1.07	0.93 to 1.24	0.58	1.09	0.94 to 1.26	0.39
eGFRcys	1.15	0.98 to 1.35	0.29	1.18	1.00 to 1.39	0.21	1.20	0.96 to 1.50	0.19
eGFRcyscre	1.11	0.97 to 1.28	0.43	1.10	0.95 to 1.29	0.44	1.09	0.93 to 1.27	0.43
GDF-15
mGFR	1.28	0.74 to 2.23		1.09	0.95 to 1.24		1.12^b	1.01 to 1.26^b
eGFRcre	1.10	0.95 to 1.28	0.61	1.06	0.95 to 1.18	0.79	1.01	0.85 to 1.19	0.28
eGFRcys	1.69	0.96 to 2.96	0.50	1.38	0.65 to 2.94	0.54	1.13	0.99 to 1.29	0.94
eGFRcyscre	1.19	0.83 to 1.71	0.83	1.11	1.00 to 1.25	0.77	0.96	0.75 to 1.24	0.28
Tie2
mGFR	1.02	0.87 to 1.20		0.88	0.74 to 1.04		0.90	0.76 to 1.07
eGFRcre	0.89	0.74 to 1.08	0.28^e	0.90	0.74 to 1.09	0.89	0.87	0.71 to 1.06	0.79
eGFRcys	1.29^b	1.09 to 1.52^b	0.05	1.14	0.95 to 1.35	0.04^b	1.12	0.89 to 1.41	0.13
eGFRcyscre	1.04	0.88 to 1.23	0.88	0.99	0.83 to 1.17	0.37	0.94	0.78 to 1.12	0.76
MMP7
mGFR	1.76^b	1.49 to 2.08^b		1.58^b	1.32 to 1.90^b		1.77^b	1.44 to 2.16^b
eGFRcre	1.54^b	1.31 to 1.81^b	0.27	1.46^b	1.23 to 1.72^b	0.50	1.34^b	1.13 to 1.59^b	0.04^b
eGFRcys	1.90^b	1.62 to 2.24^b	0.50	1.86^b	1.57 to 2.20^b	0.21	1.75^b	1.37 to 2.23^b	0.94
eGFRcyscre	1.83^b	1.56 to 2.15^b	0.74	1.71^b	1.45 to 2.02^b	0.55	1.52^b	1.27 to 1.81^b	0.27
suPAR
mGFR	1.06	0.94 to 1.19		0.99	0.83 to 1.18		0.99	0.83 to 1.17
eGFRcre	1.05	0.94 to 1.18	0.96	1.02	0.90 to 1.15	0.77	1.00	0.86 to 1.16	0.94
eGFRcys	1.14	0.98 to 1.31	0.46	1.13	1.00 to 1.27	0.23	1.04	0.85 to 1.27	0.70
eGFRcyscre	1.11	0.98 to 1.26	0.60	1.07	0.95 to 1.20	0.46	1.02	0.88 to 1.18	0.79
MMP2
mGFR	1.00	0.85 to 1.19		1.03	0.87 to 1.21		1.03	0.88 to 1.22
eGFRcre	1.03	0.88 to 1.21	0.83	1.02	0.88 to 1.19	0.96	0.99	0.84 to 1.17	0.72
eGFRcys	0.98	0.82 to 1.17	0.82	0.95	0.79 to 1.14	0.51	0.84	0.66 to 1.07	0.17
eGFRcyscre	1.03	0.88 to 1.20	0.84	1.01	0.87 to 1.18	0.87	1.00	0.85 to 1.17	0.75
Umod
mGFR	0.80^b	0.68 to 0.95^b		0.99	0.83 to 1.18		0.94	0.78 to 1.13
eGFRcre	0.81^b	0.67 to 0.98^b	0.93^f	0.79^b	0.65 to 0.97^b	0.11	0.84	0.69 to 1.03	0.43
eGFRcys	0.52^b	0.43 to 0.63^b	<0.001^b	0.61^b	0.49 to 0.75^b	<0.001^b	0.85	0.62 to 1.16	0.57
eGFRcyscre	0.72^b	0.60 to 0.87^b	0.39	0.77^b	0.63 to 0.94^b	0.07	0.89	0.71 to 1.11	0.70
Gal-3
mGFR	1.00	0.84 to 1.20		1.10	0.91 to 1.34		1.15	0.96 to 1.38
eGFRcre	1.19^b	1.04 to 1.37^b	0.13	1.18	1.02 to 1.36	0.60	1.11	0.95 to 1.30	0.77
eGFRcys	1.10	0.96 to 1.26	0.41	1.25	1.06 to 1.47	0.33	0.97	0.76 to 1.24	0.26
eGFRcyscre	1.21^b	1.06 to 1.38^b	0.09	1.25	1.08 to 1.45	0.31	1.16	0.99 to 1.36	0.96

Accelerated GFR decline defined as the 10% with the steepest annual GFR decline slope for the corresponding GFR method. CD40Lig, CD40 ligand receptor; CI, confidence interval; cre, creatinine; cys, cystatin C; FABP4, fatty acid binding protein 4; Gal-3, galectin-3; GDF-15, growth/differentiation factor 15; MCP-1, monocyte chemoattractant protein-1; mGFR, measured GFR; MMP2, matrix metalloproteinase 2; MMP7, matrix metalloproteinase 7; OR, odds ratio; suPAR, soluble urokinase-type plasminogen activator receptor; Tie2, TEK tyrosine kinase; TNFR-2, TNF receptor 2; TRAIL-R2, TNF-related apoptosis-inducing ligand receptor 2; Umod, uromodulin.

Model 1: Sex, age, body mass index, smoke (now, previously, newer).

Model 2: model 1+baseline GFR.

P value for statistically significant differences between measured GFR and the respective eGFR from creatinine, cystatin C, or both.

Log2 transformed.

Statistically significant association between protein and accelerated GFR decline or statistically significant difference between mGFR and eGFR.

A statistically significant difference between eGFRcre and eGFRcys:

P value: <0.001.

P value: 0.004.

P value: 0.001.